Clinical Research Program

NexGen Oncology recognizes the important role clinical trials play in the fight against cancer, and strives to accelerate the introduction of new therapies to the community and facilitate rapid FDA approval of new cancer treatment products. In order to protect patients and ensure consistent testing procedures, strict clinical protocols must be adhered to.

Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

Presently NexGen Oncology is actively involved in the following areas:

  • Breast Cancer
  • Leukemia
  • Lung Cancer
  • Colon Cancer
  • Prostate Cancer
  • Teleoncology

Participation in clinical trials is voluntary and patients are required to sign an informed consent form before enrolling in a trial. The consent form describes what will be involved in the trail, including the possible risks and benefits. NexGen Oncology participates in phase II and III clinical trials. Consult with your physician about clinical trials for which you may be eligible.